Literature DB >> 23235469

Glomerular hyperfiltration and proteinuria in transfusion-independent patients with β-thalassemia intermedia.

Fuad N Ziyadeh1, Khaled M Musallam, Naji S Mallat, Samir Mallat, Fadel Jaber, Ali Abdulnabi Mohamed, Suzanne Koussa, Ali T Taher.   

Abstract

BACKGROUND/AIMS: Renal manifestations have been described in β-thalassemia major and were attributed to transfusional iron overload and chelation therapy. Patients with the milder phenotype, β-thalassemia intermedia (TI), remain largely transfusion and iron chelation independent while enduring a chronic hemolytic anemia and primary iron overload. Data on renal function in patients with TI is lacking.
METHODS: In this cross-sectional study of 50 TI patients, we evaluated the association of estimated glomerular filtration rate (eGFR) and urinary protein to creatinine (UPr/UCr) ratio with relevant patient, disease and laboratory indices.
RESULTS: The median age of patients was 28 years (44% males). The eGFR was >90 ml/min/1.73 m(2) in all patients, with a median value of 142.3 ml/min/1.73 m(2). The median UPr/UCr ratio was 213.2 mg/g. There was a negative correlation between age and eGFR, while the UPr/UCr ratio correlated positively with markers of anemia, hemolysis and iron overload. A total of 24 (48%) patients had evidence of glomerular hyperfiltration, while 7 (14%) had proteinuria (UPr/UCr ratio >500 mg/g). Patients with proteinuria were characterized by elevated liver iron concentration (>7 mg Fe/g dry weight), non-transferrin-bound iron levels and nucleated red blood cell counts.
CONCLUSIONS: A considerable proportion of TI patients show evidence of abnormally elevated eGFR, with a declining trend towards advancing age. The occurrence of proteinuria is associated with anemia, hemolysis and iron toxicity.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 23235469     DOI: 10.1159/000339787

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  10 in total

Review 1.  Management of non-transfusion-dependent thalassemia: a practical guide.

Authors:  Ali T Taher; Maria Domenica Cappellini
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

2.  GFR in Patients with β-Thalassemia Major.

Authors:  Gai Milo; Revital Feige Gross Nevo; Idit Pazgal; Anat Gafter-Gvili; Ofer Shpilberg; Uzi Gafter; Arie Erman; Pinhas Stark
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-11       Impact factor: 8.237

3.  High phosphate intake induces bone loss in nephrectomized thalassemic mice.

Authors:  Sasithorn Wanna-Udom; Chainarong Luesiripong; Nithidol Sakunrangsit; Piyanuch Metheepakornchai; Sitthichai Intharamonthian; Saovaros Svasti; Matthew B Greenblatt; Asada Leelahavanichkul; Sutada Lotinun
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

Review 4.  Non-transfusion-dependent thalassemias.

Authors:  Khaled M Musallam; Stefano Rivella; Elliott Vichinsky; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

Review 5.  Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Paolo Ricchi; Maria Marsella
Journal:  Drug Des Devel Ther       Date:  2015-12-16       Impact factor: 4.162

6.  Nephrectomy Does not Exacerbate Cancellous Bone loss in Thalassemic Mice.

Authors:  Sutada Lotinun; Korakot Atjanasuppat; Jutatip Limsuvech; Asada Leelahavanichkul; Saovaros Svasti; Nateetip Krishnamra
Journal:  Sci Rep       Date:  2020-05-08       Impact factor: 4.379

7.  Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.

Authors:  Osama Tanous; Yossi Azulay; Raphael Halevy; Tal Dujovny; Neta Swartz; Raul Colodner; Ariel Koren; Carina Levin
Journal:  BMC Nephrol       Date:  2021-12-20       Impact factor: 2.388

Review 8.  Thalassemia Intermedia: Chelator or Not?

Authors:  Yen-Chien Lee; Chi-Tai Yen; Yen-Ling Lee; Rong-Jane Chen
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208

9.  IgA nephropathy associated with thalassemia: a case report.

Authors:  Jun Ni; Caifeng Zhu; Xiaoqiu Ni; Jiazhen Yin
Journal:  BMC Nephrol       Date:  2020-05-14       Impact factor: 2.388

10.  β-Thalassemia minor & renal tubular dysfunction: is there any association?

Authors:  Mohsen Vakili Sadeghi; Maryam Mirghorbani; Roghayeh Akbari
Journal:  BMC Nephrol       Date:  2021-12-07       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.